In:
Oncology Research and Treatment, S. Karger AG, Vol. 43, No. 11 ( 2020), p. 628-636
Abstract:
〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 5-Fluorouracil (FU) is one of the most commonly used cytostatic drugs in the systemic treatment of cancer. Treatment with FU may cause severe or life-threatening side effects and the treatment-related mortality rate is 0.2–1.0%. 〈 b 〉 〈 i 〉 Summary: 〈 /i 〉 〈 /b 〉 Among other risk factors associated with increased toxicity, a genetic deficiency in dihydropyrimidine dehydrogenase (DPD), an enzyme responsible for the metabolism of FU, is well known. This is due to variants in the DPD gene ( 〈 i 〉 DPYD 〈 /i 〉 ). Up to 9% of European patients carry a DPD gene variant that decreases enzyme activity, and DPD is completely lacking in approximately 0.5% of patients. Here we describe the clinical and genetic background and summarize recommendations for the genetic testing and tailoring of treatment with 5-FU derivatives. The statement was developed as a consensus statement organized by the German Society for Hematology and Medical Oncology in cooperation with 13 medical associations from Austria, Germany, and Switzerland. 〈 b 〉 〈 i 〉 Key Messages: 〈 /i 〉 〈 /b 〉 (i) Patients should be tested for the 4 most common genetic 〈 i 〉 DPYD 〈 /i 〉 variants before treatment with drugs containing FU. (ii) Testing forms the basis for a differentiated, risk-adapted algorithm with recommendations for treatment with FU-containing drugs. (iii) Testing may optionally be supplemented by therapeutic drug monitoring.
Type of Medium:
Online Resource
ISSN:
2296-5270
,
2296-5262
Language:
English
Publisher:
S. Karger AG
Publication Date:
2020
detail.hit.zdb_id:
2749752-5
Bookmarklink